Lexeo Therapeutics, Inc. (LXEO)

Market Cap	518.37M
Revenue (ttm)	n/a
Net Income (ttm)	-114.17M
Shares Out	54.00M
EPS (ttm)	-3.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,007,896
Open	9.23
Previous Close	9.22
Day's Range	9.23 - 10.04
52-Week Range	1.45 - 11.72
Beta	n/a
Analysts	Strong Buy
Price Target	18.13 (+88.85%)
Earnings Date	Nov 12, 2025

About LXEO

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 3, 2023
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: LXEO
• Website: https://www.lexeotx.com

Analyst Summary

According to 8 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price target is $18.13, which is an increase of 88.85% from the latest price.

Price Target

$18.13

(88.85% upside)

Analyst Consensus: Strong Buy